Q1 2024 Earnings Estimate for Stoke Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:STOK)

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Research analysts at HC Wainwright issued their Q1 2024 earnings per share estimates for Stoke Therapeutics in a research report issued to clients and investors on Tuesday, March 26th. HC Wainwright analyst A. Fein expects that the company will earn ($0.63) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.28) per share. HC Wainwright also issued estimates for Stoke Therapeutics’ Q2 2024 earnings at ($0.63) EPS, Q3 2024 earnings at ($0.63) EPS, Q4 2024 earnings at ($0.63) EPS, FY2024 earnings at ($2.62) EPS, FY2025 earnings at ($3.45) EPS, FY2026 earnings at ($2.59) EPS, FY2027 earnings at ($0.91) EPS and FY2028 earnings at $0.18 EPS.

Other equities analysts also recently issued research reports about the company. Wedbush lifted their price target on Stoke Therapeutics from $13.00 to $17.00 and gave the company an “outperform” rating in a research note on Tuesday. JPMorgan Chase & Co. upped their price target on Stoke Therapeutics from $6.00 to $13.00 and gave the stock a “neutral” rating in a report on Tuesday. Needham & Company LLC raised their price objective on Stoke Therapeutics from $14.00 to $22.00 and gave the company a “buy” rating in a research note on Tuesday. Canaccord Genuity Group upped their target price on shares of Stoke Therapeutics from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, TD Cowen raised shares of Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.63.

Stoke Therapeutics Trading Up 37.7 %

STOK opened at $14.17 on Thursday. The company has a market cap of $656.07 million, a price-to-earnings ratio of -5.98 and a beta of 0.68. The company’s fifty day moving average price is $5.88 and its two-hundred day moving average price is $4.95. Stoke Therapeutics has a 1-year low of $3.35 and a 1-year high of $16.40.

Insiders Place Their Bets

In other Stoke Therapeutics news, CEO Edward M. Md Kaye sold 11,150 shares of the firm’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total transaction of $68,015.00. Following the completion of the transaction, the chief executive officer now owns 69,350 shares of the company’s stock, valued at $423,035. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Stoke Therapeutics news, CEO Edward M. Md Kaye sold 11,150 shares of Stoke Therapeutics stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total value of $68,015.00. Following the completion of the transaction, the chief executive officer now directly owns 69,350 shares of the company’s stock, valued at $423,035. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Stephen J. Tulipano sold 4,116 shares of the business’s stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total transaction of $25,107.60. Following the completion of the transaction, the chief financial officer now owns 20,746 shares of the company’s stock, valued at $126,550.60. The disclosure for this sale can be found here. In the last 90 days, insiders sold 37,615 shares of company stock worth $212,852. 12.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Stoke Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in Stoke Therapeutics by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 1,648,502 shares of the company’s stock valued at $8,671,000 after acquiring an additional 17,814 shares during the period. Barclays PLC raised its stake in shares of Stoke Therapeutics by 365.3% in the fourth quarter. Barclays PLC now owns 39,271 shares of the company’s stock worth $206,000 after buying an additional 30,831 shares during the period. Granahan Investment Management LLC lifted its position in shares of Stoke Therapeutics by 33.7% during the 4th quarter. Granahan Investment Management LLC now owns 1,137,887 shares of the company’s stock valued at $5,985,000 after buying an additional 286,686 shares in the last quarter. Bridgeway Capital Management LLC bought a new position in shares of Stoke Therapeutics during the 4th quarter valued at approximately $90,000. Finally, Birchview Capital LP increased its holdings in Stoke Therapeutics by 147.1% in the 4th quarter. Birchview Capital LP now owns 210,000 shares of the company’s stock worth $1,105,000 after acquiring an additional 125,000 shares in the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.